Boston, MA, March 5, 2010—Boston BioCom LLC (BBC), in collaboration with the Massachusetts General Hospital (MGH) scientists and commercial recombinant protein producers has expressed milligram quantities of BBC’s first clinical candidate fusion protein (MTB HSP70 fused with anti-mesothelin scFv) as well as the first building block of BBC’s self assembling therapeutics (MTB HSP70- avidin fusion). These proteins are currently being tested in a mouse model of ovarian cancer at MGH. The MGH scientists demonstrated that intraperitoneal treatment with MTBhsp70-scFv vaccine results in anti-mesothelin immune responses which are significantly much greater than those induced by saline or non fusion constructs . The anti-mesothelin immune response was associated with significantly prolonged survival in the experimentally treated animals versus control animals following development of clinically evident disease. Vaccinated mice, including those getting the self-assembled vaccine, were twice as likely to be free of tumor as control-treated mice with Ova Ca at autopsy at 42 – 56 days post inoculation with tumor. The work was selected for presentation at the Dana Farber Cancer Center Research Symposium on Breast and Ovarian Cancer, Boston, March 5, 2010.